Souquet P J, Chauvin F, Boissel J P, Cellerino R, Cormier Y, Ganz P A, Kaasa S, Pater J L, Quoix E, Rapp E
Service de Pneumologie, Centre Hospitalier Lyon Sud, France.
Lancet. 1993 Jul 3;342(8862):19-21. doi: 10.1016/0140-6736(93)91882-m.
We did a meta-analysis of all published polychemotherapy vs supportive care clinical trials in patients with non-resectable non small cell lung cancer. 7 studies with more than 700 patients were selected. We used the number of deaths at 3, 6, 9, 12, and 18 months as the endpoints because we were unable to obtain all the individual data. Our analysis showed a reduction in mortality during the first 6 months with polychemotherapy. Although small, this increase in survival, together with an improved quality of life, suggests that polychemotherapy should be recommended for patients with non-resectable non small cell lung cancer.
我们对所有已发表的关于不可切除的非小细胞肺癌患者接受多药化疗与支持性治疗的临床试验进行了荟萃分析。我们选取了7项涉及700多名患者的研究。由于无法获取所有个体数据，我们将3、6、9、12和18个月时的死亡人数作为终点指标。我们的分析表明，多药化疗在最初6个月可降低死亡率。尽管这种生存率的提高幅度较小，但生活质量有所改善，这表明对于不可切除的非小细胞肺癌患者，应推荐使用多药化疗。
